Let’s start up with the current stock price of Arbutus Biopharma Corporation (ABUS), which is $2.06 to be very precise. The Stock rose vividly during the last session to $2.22 after opening rate of $1.95 while the lowest price it went was recorded $1.94 before closing at $1.98.Recently in News on May 5, 2022, Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update. Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track. You can read further details here
Arbutus Biopharma Corporation had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $4.0100 on 01/03/22, with the lowest value was $1.9300 for the same time period, recorded on 05/10/22.
Arbutus Biopharma Corporation (ABUS) full year performance was -24.26%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Arbutus Biopharma Corporation shares are logging -68.31% during the 52-week period from high price, and 6.74% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.93 and $6.50.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1959416 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Arbutus Biopharma Corporation (ABUS) recorded performance in the market was -47.04%, having the revenues showcasing -39.59% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 308.84M, as it employees total of 85 workers.
The Analysts eye on Arbutus Biopharma Corporation (ABUS)
During the last month, 0 analysts gave the Arbutus Biopharma Corporation a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 3.0300, with a change in the price was noted -1.83. In a similar fashion, Arbutus Biopharma Corporation posted a movement of -47.04% for the period of last 100 days, recording 2,415,189 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ABUS is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical rundown of Arbutus Biopharma Corporation (ABUS)
Raw Stochastic average of Arbutus Biopharma Corporation in the period of last 50 days is set at 10.08%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 14.29%. In the last 20 days, the company’s Stochastic %K was 7.02% and its Stochastic %D was recorded 15.69%.
Considering, the past performance of Arbutus Biopharma Corporation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -47.04%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -41.14%, alongside a downfall of -24.26% for the period of the last 12 months. The shares increased approximately by -17.27% in the 7-day charts and went up by -25.63% in the period of the last 30 days. Common stock shares were lifted by -39.59% during last recorded quarter.